Tobevibart + Elebsiran + Bulevirtide
Phase 2Active 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Viral Hepatitis
Conditions
Viral Hepatitis
Trial Timeline
Aug 5, 2025 → Jul 1, 2030
NCT ID
NCT07142811About Tobevibart + Elebsiran + Bulevirtide
Tobevibart + Elebsiran + Bulevirtide is a phase 2 stage product being developed by Vir Biotechnology for Viral Hepatitis. The current trial status is active. This product is registered under clinical trial identifier NCT07142811. Target conditions include Viral Hepatitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07142811 | Phase 2 | Active |
| NCT07128550 | Phase 3 | Recruiting |
Competing Products
17 competing products in Viral Hepatitis